Ready to level up your skills? 📚 Take a weekend for yourself and dive into the knowledge waiting for you at EAS Academy! We've got you covered with resources designed to help you grow personally and professionally. Invest in your future! eas.to/EASAcademy Prof Kausik Ray FMedSci

Luca Valenti a great scientist and friend. Always spot on when he gives a lecture! A true inspiration!

This is a proof of concept that there are at least two types of steatotic liver disease with different clinical trajectories. One causing aggressive liver disease and the other less aggressive but entwined in the cardiometabolic syndrome. This is just a starting point!

Wir gratulieren herzlich! Máté Kiss, Doktoratsabsolvent der #MedUniWien , wurde für eine #Atherosklerose -Studie von der European Atherosclerosis Society mit dem Young Investigator Award in der Kategorie „Basic #Science #Award “ ausgezeichnet. Erfahren Sie mehr! ⬇ bit.ly/3J5Wj85

Some Lp(a) education. I have found many clinicians are confused when they hear about 'small Lp(a) particles.' The 'small' refers to the lower molecular weight (hence smaller than the higher MW) isoforms of apoprotein (a). 'Size' does not refer to the diameter of the LDL moiety of…

👉What Causes Premature Coronary Artery Disease?

😳Could you explain why this review doesn't mention Lp(a) even once?

🤦🏻It also confusingly mixes risk factors, risk markers, enhancers, and other elements when discussing 'causes'

link.springer.com/journal/11883/…

🍀🌿 As spring arrives, it means that the EAS Congress 2024 is coming up soon. This is one of your last chances to save money when registering. We're also starting a joint webinar series with the EAS LatAm group. Find out more: eas.to/NewsApr9_2024T Prof Kausik Ray FMedSci

👉Low-dose colchicine for atherosclerosis: long-term safety

☝️When appropriately prescribed to patients without significant renal or hepatic impairment, reports of myelosuppression, myotoxicity, and serious drug–drug interactions are rare and no more frequent than placebo,…

📢Enjoy our recently published study!
👉Among 2 million Greeks taking #LLM , 45.4% were at least high #CV risk, but only 5.5% were on dLLT or tLLT
🤔High #persistence , low #adherence
⚠️ #LDL was above targets in over two-thirds
EVANGELOS LIBEROPOULOS
Dimitrios Terentes-Printzios
sciencedirect.com/science/articl…

🌿 Join us in making a difference at the #EASCongress2024 !
We're proud to partner with UNICEF for a special sustainability initiative. Donate to UNICEF when using the cloakroom, and the Congress will make an additional contribution.
Learn more ➡️ bit.ly/3vTWG2j

👩‍⚕️👨‍⚕️ Are you a nurse or healthcare professional in lipid clinics, ready to tackle atherosclerotic vascular disease challenges in your daily work? Enroll in our new Certificate in Lipidology! Let your clinic team know & enhance their skills: eas.to/CertNurHCP2024 Prof Kausik Ray FMedSci

Our analysis on #FH #patients has just been published!
#HoFH and #heFH are in fact two #diseases , for those who still do not know about this.

Look for the critical #miRNAs and their target #genes associated with FH and its #severity . See how helpful they can be when your…

The 💡 findings by Sophie Gu Gregg W. Stone MD Charis Costopoulos Diaa Hakim may inform targeted revascularisation vs. conservative management strategies
🔗atherosclerosis-journal.com/article/S0021-…
European Atherosclerosis Society Elsevier Cardiology #CvPrev

Our Chair Manfred Weber on our next #EPP4Health pledge:

'We managed the EU Cancer Plan in this mandate, as promised.

Now, we want a plan against cardiovascular diseases in Europe.'

👇Watch more.
epp.group/1n6dkc2s

Women are twice as likely to die from cardiovascular disease as from all types of cancer combined.

Hear from Manfred Weber and ESC President Franz Weidinger about how EU action can lead to substantial progress.

🤳Full talk here: epp.group/1n6dkc2s
#EPP4Health

Great disparities persist in cardiovascular death rates among EU countries, according to ESC President.

This is unacceptable.

There cannot be first- and second-class Europeans.

Time for an EU Cardiovascular Health Plan.

#EPP4Health Manfred Weber
epp.group/1n6dkc2s

Every year in the EU:
🔴more than 6 mil. new cases of cardiovascular disease are diagnosed
🔴over 1.7 mil. people die from circulatory system diseases

We need concrete objectives and funding to reduce cardiovascular disease.

#EPP4Health #EuropeProtects epp.group/protects

Sixty million people live with cardiovascular disease in Europe. It is the biggest killer in our Union, and decisive action must be taken.

Watch ESC President and our Chair Manfred Weber on how EU action can drive significant change.

epp.group/1n6dkc2s #EPP4Health

We can do much at the EU level to improve cardiovascular health, from raising awareness to a robust strategy.

Building on our cancer achievements, we are now committed to shaping an EU Cardiovascular Health Plan.

Manfred Weber⤵️
#EPP4Health

Safety & tolerability of #zerlasiran examined in individuals with #Lpa ≥150 nmol/L.
👌No serious adverse events observed. 💪Consistent reductions in Lpa over time.
👍Promising results supporting further development.
#zerlasiran #lipoprotein_a
buff.ly/3U7Mfle